FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...
The developers of sustained acoustic medicine technology and the sam® wearable ultrasound device continue mission of ...
In 2019, BMS made a big bet on Sotyktu by deciding to keep the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, BMS sold its mega-blockbuster Otezla to Amgen for ...
The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...
Exposure to fine particulate matter and traffic-related gaseous pollutants were associated with an increased risk for late-onset RA.
Upadacitinib may improve self-reported sleep quality at 3 months in patients with rheumatoid arthritis, with sustained benefits seen over the long term.
Herbs: Guggulu helps manage joint pain, while Triphala helps to detoxify and digest food. Fenugreek works to manage joint inflammation. Spices like turmeric, garlic, cumin, and fennel have ...
Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results